Education
About Us
Working with TipRanks
Follow Us
Heron Therapeutics (HRTX)
NASDAQ:HRTX
HRTX Analyst Ratings
Strong Buy
4 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
HRTX Stock 12 Month Forecast
Average Price Target
$4.50
▲(228.47% Upside)
| Highest Price Target$6.00 | Average Price Target$4.50 | Lowest Price Target$3.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Northland Securities
$4
Buy
191.97%
Upside
Reiterated
11/05/25
Needham
$3
Buy
118.98%
Upside
Reiterated
11/04/25
Heron Therapeutics: Buy Rating Affirmed Amid Promising Product Developments and Underappreciated Market PotentialWe maintain our Buy rating and $3PT, based on a current valuation that under-appreciates the potential of HRTX's portfolio, esp. Zynrelf and Aponvie, that appear set to drive top-line growth.
H.C. Wainwright
$6
Buy
337.96%
Upside
Reiterated
11/04/25
Promising Growth and Strategic Initiatives Justify Buy Rating for Heron TherapeuticsValuation and Risks. We base our valuation and 12-month price target on our discounted cash flow. We use a 13.0% weighted average cost of capital (WACC), and an 13.5x exit multiple on our 2031 estimates. The key risk to our investment thesis and forecasts is commercial execution by Heron. Other key risks include: reimbursement risk, intellectual property risk and competitive pressures. H.C. WAINWRIGHT & CO.
Jefferies
$5
Buy
264.96%
Upside
Reiterated
11/04/25
Positive Outlook for Heron Therapeutics Driven by Zynrelef and Aponvie GrowthWeekly unit demand showed Oct's demand was sig above September, though mgmt cautions it is preliminary single-month data in Q4. Co also expects the NOPAIN Act to continue gaining traction and serve as a tailwind, improving access/coverage across government and commercial payers. We confirmed with mgmt that the development of the prefilled syringe remains on track, with registrational mfg already initiated and launch expected in 2027, which will pot'l take Zynrelef to another level.
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Northland Securities
$4
Buy
191.97%
Upside
Reiterated
11/05/25
Needham
$3
Buy
118.98%
Upside
Reiterated
11/04/25
Heron Therapeutics: Buy Rating Affirmed Amid Promising Product Developments and Underappreciated Market PotentialWe maintain our Buy rating and $3PT, based on a current valuation that under-appreciates the potential of HRTX's portfolio, esp. Zynrelf and Aponvie, that appear set to drive top-line growth.
H.C. Wainwright
$6
Buy
337.96%
Upside
Reiterated
11/04/25
Promising Growth and Strategic Initiatives Justify Buy Rating for Heron TherapeuticsValuation and Risks. We base our valuation and 12-month price target on our discounted cash flow. We use a 13.0% weighted average cost of capital (WACC), and an 13.5x exit multiple on our 2031 estimates. The key risk to our investment thesis and forecasts is commercial execution by Heron. Other key risks include: reimbursement risk, intellectual property risk and competitive pressures. H.C. WAINWRIGHT & CO.
Jefferies
$5
Buy
264.96%
Upside
Reiterated
11/04/25
Positive Outlook for Heron Therapeutics Driven by Zynrelef and Aponvie GrowthWeekly unit demand showed Oct's demand was sig above September, though mgmt cautions it is preliminary single-month data in Q4. Co also expects the NOPAIN Act to continue gaining traction and serve as a tailwind, improving access/coverage across government and commercial payers. We confirmed with mgmt that the development of the prefilled syringe remains on track, with registrational mfg already initiated and launch expected in 2027, which will pot'l take Zynrelef to another level.
Best Analysts Covering Heron Therapeutics
1 Month
xxx
Success Rate
9/23 ratings generated profit
Average Return
-4.45%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 39.13% of your transactions generating a profit, with an average return of -4.45% per trade.
3 Months
xxx
Success Rate
15/31 ratings generated profit
Average Return
+1.84%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 48.39% of your transactions generating a profit, with an average return of +1.84% per trade.
1 Year
Success Rate
5/23 ratings generated profit
Average Return
-23.72%
reiterated a buy rating last month
Copying Brandon Folkes's trades and holding each position for 1 Year would result in 21.74% of your transactions generating a profit, with an average return of -23.72% per trade.
2 Years
xxx
Success Rate
7/29 ratings generated profit
Average Return
-31.92%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 24.14% of your transactions generating a profit, with an average return of -31.92% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
HRTX Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
3
3
3
5
4
Buy
0
0
0
0
0
Hold
14
9
11
5
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
17
12
14
10
10
Each month's total comprises the sum of three months' worth of ratings.
HRTX Financial Forecast
HRTX Stock Forecast FAQ
What is HRTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Heron Therapeutics’s 12-month average price target is 4.50.
What is HRTX’s upside potential, based on the analysts’ average price target?
Heron Therapeutics has 228.47% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is HRTX a Buy, Sell or Hold?
Heron Therapeutics has a consensus rating of Strong Buy which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.
What is Heron Therapeutics’s price target?
The average price target for Heron Therapeutics is 4.50. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $6.00 ,the lowest forecast is $3.00. The average price target represents 228.47% Increase from the current price of $1.37.
The highest analyst price target is $6.00 ,the lowest forecast is $3.00. The average price target represents 228.47% Increase from the current price of $1.37.
What do analysts say about Heron Therapeutics?
Heron Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
How can I buy shares of HRTX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.